SCHEMBL6001747

SCHEMBL6001747

FC(F)(F)Sc1ccc(CCc2ccc(SC(F)(F)F)cc2)cc1

nearest known ligand 0.65

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PTPRZ1 P23471 4/20 0.65
PTPN1 P18031 2/20 0.65
ALDH1A1 P00352 2/20 0.56
KDM4E B2RXH2 1/20 0.56
TDP1 Q9NUW8 1/20 0.56
EPHX2 P34913 1/20 0.42
NR1H4 Q96RI1 1/20 0.42
MAPT P10636 1/20 0.40
ATM Q13315 1/20 0.40
KIF11 P52732 1/20 0.39
LMNA P02545 1/20 0.39
HTT P42858 1/20 0.39
ALKBH5 Q6P6C2 1/20 0.39
FTO Q9C0B1 1/20 0.39
TAAR1 Q96RJ0 1/20 0.37
CA1 P00915 1/20 0.36
CA2 P00918 1/20 0.36
CA9 Q16790 1/20 0.36
MBOAT4 Q96T53 1/20 0.36
GFER P55789 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13064734 0.87 PTPRZ1 (0.57) PTPRZ1PTPN1ALDH1A1KDM4ETDP1
SCHEMBL5537909 0.87 PTPRZ1 (0.57) PTPRZ1PTPN1ALDH1A1KDM4ETDP1
SCHEMBL3630994 0.87 PTPRZ1 (0.57) PTPRZ1PTPN1ALDH1A1KDM4ETDP1
SCHEMBL696549 0.87 PTPRZ1 (0.57) PTPRZ1PTPN1ALDH1A1KDM4ETDP1
SCHEMBL1161025 0.87 KDM4E (0.59) PTPRZ1PTPN1ALDH1A1KDM4ETDP1
SCHEMBL18998006 0.85 PTPRZ1 (0.65) PTPRZ1PTPN1ALDH1A1KDM4ETDP1
SCHEMBL5544527 0.83 PTPRZ1 (0.53) PTPRZ1PTPN1ALDH1A1KDM4ETDP1
SCHEMBL5538192 0.82 PTPRZ1 (0.52) PTPRZ1PTPN1ALDH1A1KDM4ETDP1
SCHEMBL257111 0.81 PTPRZ1 (0.61) PTPRZ1PTPN1ALDH1A1KDM4ETDP1
SCHEMBL95318 0.81 PTPRZ1 (0.61) PTPRZ1PTPN1ALDH1A1KDM4ETDP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1212296-B9 PHOSPHATE MIMICS AND METHODS OF TREATMENT USING PHOSPHATASE INHIBITORS SUGEN INC (US) 2006-05-10 EP disclosed
EP-1212296-B1 PHOSPHATE MIMICS AND METHODS OF TREATMENT USING PHOSPHATASE INHIBITORS SUGEN INC (US) 2005-11-09 EP disclosed
US-20040138255-A1 Phosphate mimics and methods of treatment using phosphatease inhibitors SUGEN, INC. 2004-07-15 US disclosed
US-6596772-B1 Relates to trifluoromethyl sulfonyl and trifluoromethyl sulfonamido compounds and the physiologically acceptable salts and the prodrugs thereof. These compounds are expected to modulate the activity of protein tyrosine enzymes which are SUGEN, INC. 2003-07-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040138255-A1 Phosphate mimics and methods of treatment using phosphatease inhibitors PPP4C, PTPRO, PTPRS PTPRZ1 52/4885PTPN1 23/4885ALDH1A1 4477/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.